Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25793081 | 0.90 | ALDH1A1 (0.55) | EPHX2ALDH1A1MAPK14CNR2CNR1 | |
| SCHEMBL25793076 | 0.85 | ALDH1A1 (0.51) | EPHX2ALDH1A1MAPK14CNR2CNR1 | |
| SCHEMBL9893018 | 0.84 | ALDH1A1 (0.71) | ALDH1A1MAPK14CNR2CNR1 | |
| SCHEMBL9891522 | 0.83 | ALDH1A1 (0.53) | EPHX2ALDH1A1MAPK14IDO1CNR2 | |
| SCHEMBL9891929 | 0.83 | EPHX2 (0.51) | EPHX2ALDH1A1MAPK14IDO1CNR2 | |
| SCHEMBL4284384 | 0.83 | EPHX2 (0.53) | EPHX2ALDH1A1MAPK14IDO1CNR2 | |
| SCHEMBL14647434 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPK14CNR2CNR1CA2 | |
| SCHEMBL9892898 | 0.82 | EPHX2 (0.50) | EPHX2ALDH1A1MAPK14IDO1CNR2 | |
| SCHEMBL5067070 | 0.81 | EPHX2 (0.46) | EPHX2ALDH1A1MAPK14IDO1CNR2 | |
| SCHEMBL13413831 | 0.79 | ALDH1A1 (0.51) | EPHX2ALDH1A1MAPK14CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| EP-0375670-B1 | Process for preparing 3-polyfluoroalkylisoxazolylamines | SHIONOGI & CO (JP) | 1997-08-06 | — | — | EP | disclosed |
| EP-0375670-A2 | Process for preparing 3-polyfluoroalkylisoxazolylamines | SHIONOGI & CO., LTD. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4797492-A | INTERMEDIATES FOR BACTERICIDES; HERBICIDES OR FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 1989-01-10 | — | — | US | disclosed |
| EP-0220947-A2 | Polyfluoroalkylisoxazolylamines, their preparation and use | SHIONOGI & CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | EPHX2 1702/4885ALDH1A1 4327/4885MAPK14 447/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | EPHX2 1883/4885ALDH1A1 4354/4885MAPK14 454/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EPHX2 1990/4885ALDH1A1 4542/4885MAPK14 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.